Trial Profile
The Reggio Emilia study on bromfenac for patients with Pseudo EXfoliation syndrome undergoing cataract surgery: the REPEX study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Bromfenac (Primary) ; Tobramycin/dexamethasone
- Indications Ocular inflammation
- Focus Therapeutic Use
- Acronyms REPEX Study
- 28 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 07 Oct 2014 New source identified and integrated (ClinicalTrials.gov record, NCT02137161).
- 01 Jul 2014 New trial record